vs
Side-by-side financial comparison of John Marshall Bancorp, Inc. (JMSB) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $16.8M, roughly 1.1× John Marshall Bancorp, Inc.). SCYNEXIS INC runs the higher net margin — 65.7% vs 36.3%, a 29.4% gap on every dollar of revenue. Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 15.3%).
John Marshall Bancorp, Inc. is a U.S.-based bank holding company that operates through its wholly owned subsidiary John Marshall Bank. It provides a full suite of commercial and consumer banking products including deposit accounts, commercial loans, residential mortgages, and personal financial services, primarily serving retail customers and small-to-mid-sized businesses across the U.S. Mid-Atlantic region.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
JMSB vs SCYX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.8M | $18.6M |
| Net Profit | $6.1M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | — | 56.3% |
| Net Margin | 36.3% | 65.7% |
| Revenue YoY | — | 1808.5% |
| Net Profit YoY | 26.8% | 376.5% |
| EPS (diluted) | $0.43 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $16.8M | — | ||
| Q4 25 | $16.4M | $18.6M | ||
| Q3 25 | $16.3M | $334.0K | ||
| Q2 25 | $15.4M | $1.4M | ||
| Q1 25 | $14.6M | $257.0K | ||
| Q4 24 | $14.3M | $977.0K | ||
| Q3 24 | $13.8M | $660.0K | ||
| Q2 24 | $12.6M | $736.0K |
| Q1 26 | $6.1M | — | ||
| Q4 25 | $5.9M | $12.3M | ||
| Q3 25 | $5.4M | $-8.6M | ||
| Q2 25 | $5.1M | $-6.9M | ||
| Q1 25 | $4.8M | $-5.4M | ||
| Q4 24 | $4.8M | — | ||
| Q3 24 | $4.2M | $-2.8M | ||
| Q2 24 | $3.9M | $-14.5M |
| Q1 26 | — | — | ||
| Q4 25 | 47.4% | 56.3% | ||
| Q3 25 | 42.2% | -2516.5% | ||
| Q2 25 | 42.7% | -701.0% | ||
| Q1 25 | 42.4% | -3350.2% | ||
| Q4 24 | 42.5% | — | ||
| Q3 24 | 38.8% | -1563.6% | ||
| Q2 24 | 39.7% | -1255.0% |
| Q1 26 | 36.3% | — | ||
| Q4 25 | 36.2% | 65.7% | ||
| Q3 25 | 33.2% | -2572.2% | ||
| Q2 25 | 33.1% | -504.8% | ||
| Q1 25 | 32.9% | -2097.7% | ||
| Q4 24 | 33.3% | — | ||
| Q3 24 | 30.7% | -425.5% | ||
| Q2 24 | 30.9% | -1964.4% |
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.41 | $0.25 | ||
| Q3 25 | $0.38 | $-0.17 | ||
| Q2 25 | $0.36 | $-0.14 | ||
| Q1 25 | $0.34 | $-0.11 | ||
| Q4 24 | $0.33 | — | ||
| Q3 24 | $0.30 | $-0.06 | ||
| Q2 24 | $0.27 | $-0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $150.2M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $268.1M | $49.4M |
| Total Assets | $2.4B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $150.2M | — | ||
| Q4 25 | $130.0M | $40.0M | ||
| Q3 25 | $163.6M | $37.9M | ||
| Q2 25 | $116.9M | $44.8M | ||
| Q1 25 | $169.1M | $40.6M | ||
| Q4 24 | $122.5M | $59.3M | ||
| Q3 24 | $177.2M | $68.8M | ||
| Q2 24 | $182.6M | $73.0M |
| Q1 26 | — | — | ||
| Q4 25 | $80.9M | — | ||
| Q3 25 | $80.9M | — | ||
| Q2 25 | $80.8M | — | ||
| Q1 25 | $80.8M | — | ||
| Q4 24 | $80.8M | — | ||
| Q3 24 | $80.8M | — | ||
| Q2 24 | $24.7M | — |
| Q1 26 | $268.1M | — | ||
| Q4 25 | $265.6M | $49.4M | ||
| Q3 25 | $259.7M | $36.4M | ||
| Q2 25 | $253.7M | $44.5M | ||
| Q1 25 | $253.0M | $50.5M | ||
| Q4 24 | $246.6M | $55.1M | ||
| Q3 24 | $243.1M | $58.5M | ||
| Q2 24 | $235.3M | $60.4M |
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.3B | $59.0M | ||
| Q3 25 | $2.3B | $51.1M | ||
| Q2 25 | $2.3B | $60.7M | ||
| Q1 25 | $2.3B | $67.9M | ||
| Q4 24 | $2.2B | $90.6M | ||
| Q3 24 | $2.3B | $99.0M | ||
| Q2 24 | $2.3B | $107.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.30× | — | ||
| Q3 25 | 0.31× | — | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | 0.32× | — | ||
| Q4 24 | 0.33× | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.11× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $22.6M | $18.4M | ||
| Q3 25 | $1.2M | $-8.7M | ||
| Q2 25 | $7.5M | $-7.5M | ||
| Q1 25 | $7.0M | $-7.5M | ||
| Q4 24 | $17.3M | $-24.0M | ||
| Q3 24 | $1.4M | $765.0K | ||
| Q2 24 | $10.2M | $-10.9M |
| Q1 26 | — | — | ||
| Q4 25 | $22.0M | — | ||
| Q3 25 | $1.2M | — | ||
| Q2 25 | $7.4M | — | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | $16.8M | — | ||
| Q3 24 | $1.3M | — | ||
| Q2 24 | $10.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | 134.7% | — | ||
| Q3 25 | 7.3% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 45.3% | — | ||
| Q4 24 | 116.9% | — | ||
| Q3 24 | 9.5% | — | ||
| Q2 24 | 80.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | 0.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.82× | 1.50× | ||
| Q3 25 | 0.23× | — | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 1.45× | — | ||
| Q4 24 | 3.61× | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 2.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JMSB
| Net Interest Income | $16.5M | 98% |
| Noninterest Income | $284.0K | 2% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
